Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 8/20 | 0.42 |
| ▸ | EP300 | Q09472 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951637 | 0.83 | ESR2 (0.38) | RBP4EP300CREBBPNR1H2ESR2 | |
| SCHEMBL2977256 | 0.80 | MAPK1 (0.57) | EP300CREBBPBRD4MAPTGPR119 | |
| SCHEMBL5952667 | 0.80 | SMN1; SMN2 (0.39) | GPR119 | |
| SCHEMBL17870541 | 0.78 | RBP4 (0.39) | RBP4EP300CREBBPBRD4MAPT | |
| SCHEMBL17870535 | 0.77 | RBP4 (0.39) | RBP4EP300CREBBPBRD4MAPT | |
| SCHEMBL5952792 | 0.77 | RBP4 (0.45) | RBP4EP300CREBBPBRD4MAPT | |
| SCHEMBL25430237 | 0.77 | ADORA1 (0.43) | RBP4EP300CREBBPBRD4MAPT | |
| SCHEMBL4792110 | 0.76 | ADORA1 (0.46) | RBP4EP300CREBBPBRD4NR1H2 | |
| SCHEMBL14520683 | 0.76 | ESR2 (0.41) | RBP4EP300CREBBPBRD4NR1H2 | |
| SCHEMBL4761735 | 0.75 | RBP4 (0.42) | RBP4EP300CREBBPBRD4NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | RBP4 4853/4885EP300 1058/4885CREBBP 1474/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | RBP4 4867/4885EP300 1361/4885CREBBP 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.